Literature DB >> 6522928

Cost containment of reconstituted parenteral antibiotics: personnel and supply costs associated with preparation, dispensing, and administration.

D J Tanner.   

Abstract

Time-and-motion studies were conducted to determine the time and cost associated with the dispensing, preparation, and administration of reconstituted parenteral antibiotics via the piggyback iv admixture (PBS) or volume control iv set administration (VCS) methods in six hospitals of various sizes. Supply costs were calculated for each system. National projections of potential cost savings resulting from decreased number of administrations of reconstituted parenteral antibiotics were made. The antibiotic class of parenteral cephalosporins was chosen as an example of where cost containment might be achieved. The estimated potential for total cost containment for the average hospital per hospital bed resulting from decreased number of administrations of first- and second-generation cephalosporins ranged from $76.64 (25% reduction in doses administered) to $229.92 (75% reduction) for the PBS method and, similarly, $47.02 to $141.08 for the VCS method. The projected potential national cost savings resulting from decreased number of administrations of first- and second-generation cephalosporins based on predicted antibiotic usage for 1983 ranged from $62.2 million (25% reduction in doses administered and adjusting for no conversion to intramuscular or intravenous push administrations) to $276.7 million (75% reduction). Clinicians and health-care managers should consider the cost-containment advantages provided by the substitution of newer antibiotics that permit reduced frequency of administration.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6522928     DOI: 10.1093/clinids/6.supplement_4.s924

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  13 in total

1.  Spreadsheet software program to analyse costs beyond drug acquisition price.

Authors:  J A Paladino
Journal:  Pharmacoeconomics       Date:  1992-09       Impact factor: 4.981

2.  Decision analysis in formulary decision making.

Authors:  C B Schechter
Journal:  Pharmacoeconomics       Date:  1993-06       Impact factor: 4.981

3.  Cost of hospital antimicrobial chemotherapy. A method for global cost calculation.

Authors:  I C Gyssens; C A Lennards; Y A Hekster; J W Van der Meer
Journal:  Pharm Weekbl Sci       Date:  1991-12-13

4.  In vitro antibiotic sensitivity pattern of common bacterial isolates from cases of acute bacterial meningitis with special reference to ceftriaxone.

Authors:  B N Rao; I M Kashbur; N M Shembesh; S M el Bargathy
Journal:  Indian J Pediatr       Date:  1997 Nov-Dec       Impact factor: 1.967

5.  Cost-effectiveness comparison of cefepime and ceftazidime using decision analysis.

Authors:  J A Paladino
Journal:  Pharmacoeconomics       Date:  1994-06       Impact factor: 4.981

6.  Economic evaluation of oral ofloxacin versus standard parenteral therapy in the treatment of pneumonia.

Authors:  J Menzin; D M Huse; R Richner; G Oster
Journal:  Pharmacoeconomics       Date:  1992-08       Impact factor: 4.981

7.  Cost-effectiveness of abbreviating the duration of intravenous antibacterial therapy with oral fluoroquinolones.

Authors:  K M Jensen; J A Paladino
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

8.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 9.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

10.  Cost effectiveness of cephalosporin monotherapy and aminoglycoside/ureidopenicillin combination therapy. For the treatment of febrile episodes in neutropenic patients.

Authors:  J A Paladino; L D Fong; A Forrest; R Ramphal
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.